Phase 2a trial results show laromestrocel (Lomecel-B™) improves cognitive function and brain volume in mild Alzheimer's disease patients. Longeveron Inc. announced positive results from its Phase 2a ...

MIAMI, Oct. 29, 2024 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN), a clinical stage regenerative medicine biotechnology company developing cellular therapies for life-threatening and chronic ...

On Sunday, Longeveron Inc (NASDAQ:LGVN) presented Phase 2a clinical trial data and biomarker results at the Alzheimer’s Association International Conference (AAIC). The Phase 2a CLEAR MIND trial ...

Lomecel-B™ is now known as laromestrocel, a cellular therapy for Alzheimer's and hypoplastic left heart syndrome, following WHO approval. Longeveron Inc. has announced that its cellular therapy ...

MIAMI, Dec. 20, 2023 (GLOBE NEWSWIRE) -- Longeveron Inc. (LGVN) (“Longeveron” or “Company”), a clinical stage biotechnology company developing cellular therapies for life-threatening and chronic aging ...

MIAMI, Oct. 27, 2024 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN), a clinical stage biotechnology company developing regenerative medicines, today announced that its positive long-term ...

Longeveron Inc LGVN announced the publication of Phase 1 trial results of Lomecel-B on patients with mild Alzheimer's disease (AD) in the Alzheimer's & Dementia journal. The 33-subject trial met its ...

MIAMI, Oct. 14, 2024 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN), a clinical stage biotechnology company developing regenerative medicines, today announced that its submission entitled "Lomecel ...

Oral presentation highlights findings that patients treated with Lomecel-BTM in ELPIS I, in an open-label follow-on study, experienced 5-year survival after stage 2 Glenn surgery of 100% with none ...

Findings offer potential mechanistic and clinical insights in the development of cellular therapy Lomecel-B™ for mild Alzheimer’s disease (AD) Lomecel-B™ capacity to inhibit MMP14 correlates with ...